197 related articles for article (PubMed ID: 37917101)
1. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
2. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
3. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
4. Enhancing Radioiodine Incorporation in
Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
[No Abstract] [Full Text] [Related]
5. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
Sabra MM; Dominguez JM; Grewal RK; Larson SM; Ghossein RA; Tuttle RM; Fagin JA
J Clin Endocrinol Metab; 2013 May; 98(5):E829-36. PubMed ID: 23533233
[TBL] [Abstract][Full Text] [Related]
6. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract][Full Text] [Related]
7. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
8. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
9. Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
Montes de Jesus FM; Espeli V; Paone G; Giovanella L
Endocrine; 2023 Sep; 81(3):450-454. PubMed ID: 37191938
[TBL] [Abstract][Full Text] [Related]
10. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
12. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
Jafri S; Yaqub A
Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Dunn LA; Sherman EJ; Baxi SS; Tchekmedyian V; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Ni A; Li D; Knauf JA; Pfister DG; Fagin JA; Ho AL
J Clin Endocrinol Metab; 2019 May; 104(5):1417-1428. PubMed ID: 30256977
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score-matched analysis.
Guo H; Zhang N; Hu Y; Zhang F; Huang T; Shen N
Front Endocrinol (Lausanne); 2023; 14():1158581. PubMed ID: 37664843
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
16. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract][Full Text] [Related]
17. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.
Hayes DN; Lucas AS; Tanvetyanon T; Krzyzanowska MK; Chung CH; Murphy BA; Gilbert J; Mehra R; Moore DT; Sheikh A; Hoskins J; Hayward MC; Zhao N; O'Connor W; Weck KE; Cohen RB; Cohen EE
Clin Cancer Res; 2012 Apr; 18(7):2056-65. PubMed ID: 22241789
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
Gruber JJ; Colevas AD
Oncologist; 2015 Feb; 20(2):113-26. PubMed ID: 25616432
[TBL] [Abstract][Full Text] [Related]
19. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
20. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.
de la Fouchardiere C; Oussaid N; Derbel O; Decaussin-Petrucci M; Fondrevelle ME; Wang Q; Bringuier PP; Bournaud-Salinas C; Peix JL; Lifante JC; Giraudet AL; Lopez J; Borson-Chazot F
Target Oncol; 2016 Feb; 11(1):71-82. PubMed ID: 26285789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
